MTBVAC from discovery to clinical trials in tuberculosis-endemic countries

References

• Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA. 2007;104(13):5596–5601.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Weiner J, von Reyn CF. Novel approaches to TB vaccine development. Int J Infect Dis. 2017;56:263–267.
   Web of Science ®Google Scholar
• World Health Organization (WHO). Global tuberculosis report 2016. Geneva, Switzerland: WHO Press; 2016.
   Google Scholar
• Ai JW, Ruan QL, Liu QH, et al. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5:e10.
   PubMed Web of Science ®Google Scholar
• Sadikot RT. Identifying patients at high risk of tuberculosis recurrence. Int J Mycobacteriol. 2016;5(Suppl 1):S66.
   PubMedGoogle Scholar
• WHO. BCG vaccine. WHO position paper. Wkly Epidemiol Rec. 2004;79(4):27–38.
   PubMedGoogle Scholar
• Zwerling A, Behr MA, Verma A, et al. The BCG world Atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012.
   PubMed Web of Science ®Google Scholar
• Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics. 1995;96(1 Pt 1):29–35.
   PubMed Web of Science ®Google Scholar
• Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173–1180.
   PubMed Web of Science ®Google Scholar
• Abubakar I, Pimpin L, Ariti C, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess. 2013;17(37):1–372, v–vi.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Evans TG, Hanekom WA. Tuberculosis vaccines: time for a global strategy. Sci Transl Med. 2015;7(276):276fs278.
   Web of Science ®Google Scholar
• Kaufmann SH, Cotton MF, Eisele B, et al. The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines. 2014;13(5):619–630.
   PubMed Web of Science ®Google Scholar
• Donald PR, van Zyl LE, de Villiers J. BCG vaccination status of children with tuberculous meningitis and the use of unsupervised isoniazid prophylaxis. S Afr Med J. 1995;85(3):167–170.
   PubMed Web of Science ®Google Scholar
• Wolzak NK, Cooke ML, Orth H, et al. The changing profile of pediatric meningitis at a referral centre in Cape Town, South Africa. J Trop Pediatr. 2012;58(6):491–495.
   PubMed Web of Science ®Google Scholar
• Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–1028.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ru HW, Chen FZ, et al. Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. Mol Ther. 2016;24(2):398–405.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang Y, Zheng H, et al. Genome sequencing and analysis of BCG vaccine strains. PLoS One. 2013;8(8):e71243.
   PubMed Web of Science ®Google Scholar
• Barreto ML, Pilger D, Pereira SM, et al. Causes of variation in BCG vaccine efficacy: examining evidence from the BCG REVAC cluster randomized trial to explore the masking and the blocking hypotheses. Vaccine. 2014;32(30):3759–3764.
   Web of Science ®Google Scholar
• Rodrigues LC, Pereira SM, Cunha SS, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet. 2005;366(9493):1290–1295.
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organization. Information sheet observed rate of vaccine reactions Bacille-Calmette Guérin (BCG) vaccine. 2012 Apr . Global Vaccine Safety, Immunization Vaccines and Biologicals 20, avenue Appia, Ch-1211 Geneva 27. Available from: http://www.who.int/vaccine_safety/initiative/tools/BCG_Vaccine_rates_information_sheet.pdf. (Ed.^(Eds).
   Google Scholar
• WHO. The immunological basis for immunization series module 5: tuberculosis. 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241502412_eng.pdf. (Ed.^(Eds) (World Health Organization, Deparment of Immunizzation, Vaccines and Biologicals, 2011).
   Google Scholar
• Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. Clin Ther. 2013;35(2):109–114.
   PubMed Web of Science ®Google Scholar
• Aaby P, Roth A, Ravn H, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis. 2011;204(2):245–252.
   PubMed Web of Science ®Google Scholar
• Aaby P, Roth A, Biering-Sorensen S, et al. No evidence of bias in trial showing BCG reduces neonatal mortality. J Infect Dis. 2012;205(3):515–517.
   PubMed Web of Science ®Google Scholar
• Biering-Sorensen S, Aaby P, Napirna BM, et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guerin vaccination at first health center contact. Pediatr Infect Dis J. 2012;31(3):306–308.
   PubMed Web of Science ®Google Scholar
• Ota MO, Vekemans J, Schlegel-Haueter SE, et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunology. 2002;168(2):919–925.
   PubMed Web of Science ®Google Scholar
• de Castro MJ, Pardo-Seco J, Martinon-Torres F. Nonspecific (Heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clin Infect Dis. 2015;60(11):1611–1619.
   PubMed Web of Science ®Google Scholar
• Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA. 2012;109(43):17537–17542.
   PubMed Web of Science ®Google Scholar
• Netea MG, Joosten LA, Latz E, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098.
   PubMed Web of Science ®Google Scholar
• Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host & Microbe. 2011;9(5):355–361.
   PubMed Web of Science ®Google Scholar
• Arts RJ, Carvalho A, La Rocca C, et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Rep. 2016;17(10):2562–2571.
   PubMed Web of Science ®Google Scholar
• Walker KB, Brennan MJ, Ho MM, et al. The second Geneva consensus: recommendations for novel live TB vaccines. Vaccine. 2010;28(11):2259–2270.
   PubMedGoogle Scholar
• Kamath AT, Fruth U, Brennan MJ, et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine. 2005;23(29):3753–3761.
   PubMed Web of Science ®Google Scholar
• The tuberculosis prevention pipeline. 2016 Jul 15. by Mike Frick. Available from: http://pipelinereport.org/2016/tb-prevention
   Google Scholar
• Hawkridge T, Scriba TJ, Gelderbloem S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 2008;198(4):544–552.
   PubMed Web of Science ®Google Scholar
• Sander CR, Pathan AA, Beveridge NE, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med. 2009;179(8):724–733.
   PubMed Web of Science ®Google Scholar
• Scriba TJ, Tameris M, Smit E, et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med. 2012;185(7):769–778.
   PubMed Web of Science ®Google Scholar
• Scriba TJ, Kaufmann SH, Henri Lambert P, et al. Vaccination against tuberculosis with whole-cell mycobacterial vaccines. J Infect Dis. 2016;214(5):659–664.
   PubMed Web of Science ®Google Scholar
• Arbues A, Aguilo JI, Gonzalo-Asensio J, et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. 2013;31(42):4867–4873.
   PubMed Web of Science ®Google Scholar
• Stucki D, Brites D, Jeljeli L, et al. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nat Genet. 2016;48(12):1535–1543.
   PubMed Web of Science ®Google Scholar
• Chesne-Seck ML, Barilone N, Boudou F, et al. A point mutation in the two-component regulator PhoP-PhoR accounts for the absence of polyketide-derived acyltrehaloses but not that of phthiocerol dimycocerosates in Mycobacterium tuberculosis H37Ra. J Bacteriol. 2008;190(4):1329–1334.
   PubMed Web of Science ®Google Scholar
• Gonzalo-Asensio J, Soto CY, Arbues A, et al. The Mycobacterium tuberculosis phoPR operon is positively autoregulated in the virulent strain H37Rv. J Bacteriol. 2008;190(21):7068–7078.
   PubMed Web of Science ®Google Scholar
• Solans L, Aguilo N, Samper S, et al. A specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies WhiB6 as a novel ESX-1 component. Infect Immun. 2014;82(8):3446–3456.
   PubMed Web of Science ®Google Scholar
• Broset E, Martin C, Gonzalo-Asensio J. Evolutionary landscape of the Mycobacterium tuberculosis complex from the viewpoint of PhoPR: implications for virulence regulation and application to vaccine development. MBio. 2015;6(5):e01289–01215.
   PubMed Web of Science ®Google Scholar
• Brosch R, Gordon SV, Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA. 2002;99(6):3684–3689.
   PubMed Web of Science ®Google Scholar
• Boritsch EC, Brosch R. Evolution of mycobacterium tuberculosis: new insights into pathogenicity and drug resistance. Microbiol Spectr. 2016;4:5.
   Web of Science ®Google Scholar
• Andrews JR, Noubary F, Walensky RP, et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clinical Infect Dis. 2012;54(6):784–791.
   PubMed Web of Science ®Google Scholar
• Comas I, Chakravartti J, Small PM, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet. 2010;42(6):498–503.
   PubMed Web of Science ®Google Scholar
• Coscolla M, Copin R, Sutherland J, et al. M. tuberculosis T cell epitope analysis reveals paucity of antigenic variation and identifies rare variable TB antigens. Cell Host & Microbe. 2015;18(5):538–548.
   PubMed Web of Science ®Google Scholar
• Copin R, Coscolla M, Efstathiadis E, et al. Impact of in vitro evolution on antigenic diversity of mycobacterium bovis bacillus Calmette-Guerin (BCG). Vaccine. 2014;32(45):5998–6004.
   PubMed Web of Science ®Google Scholar
• Copin R, Wang X, Louie E, et al. Within host evolution selects for a dominant genotype of mycobacterium tuberculosis while T cells increase pathogen genetic diversity. PLoS Pathog. 2016;12(12):e1006111.
   PubMed Web of Science ®Google Scholar
• Yruela I, Contreras-Moreira B, Magalhaes C, et al. Mycobacterium tuberculosis complex exhibits lineage-specific variations affecting protein ductility and epitope recognition. Genome Biol Evol. 2017.
   PubMed Web of Science ®Google Scholar
• Arbués A. Construction and characterization of a new generation of phoP-based vaccines against tuberculosis [Doctorate Thesis; Thesis Director Prof. Carlos Martin Montañes]. Grupo de Genetica de Micobacterias. Available form: http://genmico.unizar.es/. Departamento de Microbioligía, Medicina Preventiva y Salud Publica (Ed.^(Eds) (Universidad de Zaragoza, Facultad de Medicina, Ed. A, 2010).
   Google Scholar
• Cox JS, Chen B, McNeil M, et al. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature. 1999;402(6757):79–83.
   PubMed Web of Science ®Google Scholar
• Kirksey MA, Tischler AD, Simeone R, et al. Spontaneous phthiocerol dimycocerosate-deficient variants of Mycobacterium tuberculosis are susceptible to gamma interferon-mediated immunity. Infect Immun. 2011;79(7):2829–2838.
   PubMed Web of Science ®Google Scholar
• Trivedi OA, Arora P, Vats A, et al. Dissecting the mechanism and assembly of a complex virulence mycobacterial lipid. Mol Cell. 2005;17(5):631–643.
   PubMed Web of Science ®Google Scholar
• Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J, et al. PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS One. 2008;3(10):e3496.
   PubMed Web of Science ®Google Scholar
• Gonzalo-Asensio JÁ. Deciphering the role of PhoP in Mycobacterium tuberculosis virulence [Doctorate Thesis; Director Prof. Carlos Martin]. Grupo de Genetica de Micobacterias. Available from: http://genmico.unizar.es/. Departamento de Microbioligía, Medicina Preventiva y Salud Publica (Ed.^(Eds) (Universidad de Zaragoza, Facultad de Medicina, Ed. A, 2006)
   Google Scholar
• Solans L, Gonzalo-Asensio J, Sala C, et al. The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in Mycobacterium tuberculosis. PLoS Pathog. 2014;10(5):e1004183.
   PubMed Web of Science ®Google Scholar
• Gonzalo Asensio J, Maia C, Ferrer NL, et al. The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. J Biol Chem. 2006;281(3):1313–1316.
   PubMed Web of Science ®Google Scholar
• Frigui W, Bottai D, Majlessi L, et al. Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. PLoS Pathog. 2008;4(2):e33.
   PubMed Web of Science ®Google Scholar
• Perez E, Samper S, Bordas Y, et al. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol. 2001;41(1):179–187.
   PubMed Web of Science ®Google Scholar
• Domenech P, Reed MB. Rapid and spontaneous loss of phthiocerol dimycocerosate (PDIM) from Mycobacterium tuberculosis grown in vitro: implications for virulence studies. Microbiology. 2009;155(Pt 11):3532–3543.
   PubMed Web of Science ®Google Scholar
• Aguilar D, Infante E, Martin C, et al. Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain. Clin Exp Immunol. 2007;147(2):330–338.
   PubMed Web of Science ®Google Scholar
• Cardona PJ, Asensio JG, Arbues A, et al. Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant. Vaccine. 2009;27(18):2499–2505.
   PubMed Web of Science ®Google Scholar
• Martin C, Williams A, Hernandez-Pando R, et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine. 2006;24(17):3408–3419.
   PubMed Web of Science ®Google Scholar
• Nambiar JK, Pinto R, Aguilo JI, et al. Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory. Eur J Immunol. 2012;42(2):385–392.
   PubMed Web of Science ®Google Scholar
• Verreck FA, Vervenne RA, Kondova I, et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. Plos One. 2009;4(4):e5264.
   PubMed Web of Science ®Google Scholar
• Williams A, Hall Y, Orme IM. Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb). 2009;89(6):389–397.
   PubMed Web of Science ®Google Scholar
• Spertini F, Audran R, Chakour R, et al. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med. 2015;3(12):953–962.
   PubMed Web of Science ®Google Scholar
• Aguilo N, Uranga S, Marinova D, et al. MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice. Tuberculosis (Edinb). 2016;96:71–74.
   PubMed Web of Science ®Google Scholar
• Boritsch EC, Khanna V, Pawlik A, et al. Key experimental evidence of chromosomal DNA transfer among selected tuberculosis-causing mycobacteria. Proc Natl Acad Sci USA. 2016;113(35):9876–9881.
   PubMed Web of Science ®Google Scholar
• McShane H, Williams A. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis (Edinb). 2014;94(2):105–110.
   PubMed Web of Science ®Google Scholar
• Orme IM. The use of animal models to guide rational vaccine design. Microbes Infect. 2005;7(5–6):905–910.
   PubMed Web of Science ®Google Scholar
• Williams A, Hatch GJ, Clark SO, et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb). 2005;85(1–2):29–38.
   PubMed Web of Science ®Google Scholar
• Clark S, Hall Y, Williams A. Animal models of tuberculosis: Guinea pigs. Cold Spring Harb Perspect Med. 2015;5(5):a018572.
   Web of Science ®Google Scholar
• Aguilo N, Toledo AM, Lopez-Roman EM, et al. Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination. Clin Vaccine Immunol. 2014;21(4):594–597.
   PubMed Web of Science ®Google Scholar
• Moliva JI, Turner J, Torrelles JB. Prospects in Mycobacterium bovis Bacille Calmette et Guerin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis? Vaccine. 2015;33(39):5035–5041.
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G, Dillon BJ, et al. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA. 2000;97(25):13853–13858.
   PubMed Web of Science ®Google Scholar
• The TuBerculosis Vaccine Initiative (TBVI) is a non-profit foundation that facilitates the discovery and development of new, safe and effective TB vaccines that are accessible and affordable for all people. Available from: www.tbvi.eu. TBVI provide independent expertis through their Product and Clinical Development Team (TBVI PDT/CDT), which has played an imporant role in MTBVAC development to date.
   Google Scholar
• Aeras is a nonprofit biotechnology organization developing new, effective TB vaccines through partnerships in both the public and private sectors, with individuals, research organizations, academic institutions, funders, policymakers and others around the world to advance TB vaccine science and development. Available from: www.aeras.org
   Google Scholar
• Bezos J, Casal C, Puentes E, et al. Evaluation of the immunogenicity and diagnostic interference caused by M. tuberculosis SO2 vaccination against tuberculosis in goats. Res Vet Sci. 2015;103:73–79.
   PubMed Web of Science ®Google Scholar
• Carpenter C, Sidney J, Kolla R, et al. A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis. 2015;95(6):713–721.
   PubMed Web of Science ®Google Scholar
• Mothe BR, Lindestam Arlehamn CS, Dow C, et al. The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans. Tuberculosis. 2015;95(6):722–735.
   PubMed Web of Science ®Google Scholar
• Lindestam Arlehamn CS, McKinney DM, Carpenter C, et al. A quantitative analysis of complexity of human pathogen-specific CD4 T cell responses in healthy M. tuberculosis infected South Africans. PLoS Pathog. 2016;12(7):e1005760.
   PubMed Web of Science ®Google Scholar
• Millington KA, Fortune SM, Low J, et al. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA. 2011;108(14):5730–5735.
   PubMed Web of Science ®Google Scholar
• Arregui S, Sanz J, Marinova D, et al. On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines. PeerJ. 2016;4:e1513.
   PubMed Web of Science ®Google Scholar
• Knight GM, Griffiths UK, Sumner T, et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci USA. 2014;111(43):15520–15525.
   PubMed Web of Science ®Google Scholar
• The Collaboration for TB Vaccine Discovery (CTVD) was lounched by BMGF in July 2015, as an international network of scientists and experts dedicated to fostering innovation, cooperation, and collaboration in the up-stream TB vaccine discovery space. Available from: www.ctvd.co
   Google Scholar
• Lin PL, Rodgers M, Smith L, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun. 2009;77(10):4631–4642.
   PubMed Web of Science ®Google Scholar
• Coleman MT, Chen RY, Lee M, et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med. 2014;6(265):265ra167.
   PubMed Web of Science ®Google Scholar
• Sharpe SA, McShane H, Dennis MJ, et al. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clinical Vaccine Immunol. 2010;17(8):1170–1182.
   PubMed Web of Science ®Google Scholar
• Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med. 2010;182(8):1073–1079.
   PubMed Web of Science ®Google Scholar
• Kagina BM, Mansoor N, Kpamegan EP, et al. Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry. J Immunol Methods. 2015;417:22–33.
   PubMed Web of Science ®Google Scholar
• Nemes E, Kagina BM, Smit E, et al. Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood. Cytometry A. 2015;87(2):157–165.
   PubMed Web of Science ®Google Scholar
• Soares AP, Scriba TJ, Joseph S, et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol. 2008;180(5):3569–3577.
   PubMed Web of Science ®Google Scholar